Susquehanna International Group, LLP Annovis Bio, Inc. Call Options Transaction History

Susquehanna International Group, LLP

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$5.27 - $15.46 $789,972 - $2.32 Million	-149,900 Reduced 44.76%	185,000 $1.49 Million
Q2 2024 Aug 15, 2024	BUY	$4.82 - $18.01 $551,408 - $2.06 Million	114,400 Added 51.88%	334,900 $1.93 Million
Q1 2024 May 07, 2024	BUY	$8.47 - $18.93 $1.16 Million - $2.59 Million	136,900 Added 163.76%	220,500 $2.62 Million
Q4 2023 Feb 14, 2024	BUY	$5.55 - $19.62 $463,980 - $1.64 Million	83,600 New	83,600 $1.56 Million

1.16M

229K

934K

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $58M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.